Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.85
Abstract: 85Background: Metformin (MET) may play a role as an anti-proliferative and anti-carcinogenic agent. Epidemiological studies have demonstrated that MET is associated with decreased prostate cancer (... read more here.
Keywords: prostate; bicalutamide without; metformin biochemical; prostate cancer ... See more keywords